Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
Esters N, et al. Among authors: bossuyt x.
Am J Gastroenterol. 2002 Jun;97(6):1458-62. doi: 10.1111/j.1572-0241.2002.05689.x.
Am J Gastroenterol. 2002.
PMID: 12094865
Free article.